Advancing Therapies with Leading Preclinical Schizophrenia Research Services

Well-Characterized Rodent Models of Schizophrenia

We offer various models that provide valuable insights into the cognitive impairments and other positive and negative symptoms associated with schizophrenia and the impact of your therapy.
 

  • Stimulant-induced activity (locomotion, headshakes, rearing and climbing)
  • Pre-pulse Inhibition of Acoustic Startle
  • Conditioned Avoidance Response
  • PCP-induced deficits in Social Interaction
  • PCP-induced deficits in Novel Object Recognition (NOR)
  • PCP-induced deficits in Social Recognition
  • MK-801-induced deficits in Reversal Learning
  • Mismatch Negativity (MMN)
  • Auditory Evoked Potentials (AEP)

Amphetamine increases locomotor activity in mice in a dose-dependent manner.

Time course for the effects of amphetamine on locomotor activity.

Antipsychotics like Haloperidol decrease amphetamine-induced locomotion in C57Bl/6J mice and Sprague Dawley rats.

Mouse

Rat

Valproate (VPA) decrease amphetamine-induced locomotion in mice.

PCP Induced Locomotion

  • Phencyclidine (PCP)-induced hyperactivity is used as a model of schizophrenia.​
  • Antipsychotics like Clozapine attenuate PCP-induced hyperlocomotion in C57Bl/6J mice.​

MK-801 Induced Locomotion

  • Phencyclidine (PCP)-induced hyperactivity is used as a model of schizophrenia.​
  • Antipsychotics like Clozapine attenuate PCP-induced hyperlocomotion in C57Bl/6J mice.​

Ketanserin inhibits DOI-induced headshake response in Sprague Dawley rats.

DOI and Psilocybin increase headshake response in C57Bl/6J mice.

Negative Symptoms: Cognitive and Social Deficits

  • Acute injection of MK-801 induces deficits in recognition index in Long Evans rats.
  • Galantamine attenuates MK-801 induced cognitive deficits in this test.
Partner with PsychoGenics to accelerate your early-stage schizophrenia research and contribute to the discovery of transformative therapies for individuals living with this complex disorder.